Vor Biopharma (VOR) Assets Average (2021 - 2026)
Vor Biopharma (VOR) posted quarterly Assets Average of $485.4 million for Q1 2026, up 284.96% year-over-year from $126.1 million in Q1 2025, and up 51.61% quarter-over-quarter from $320.2 million in Q4 2025.
Vor Biopharma (VOR) Assets Average (2021 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Assets Average for 6 consecutive years, with $485.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 284.96% year-over-year to $485.4 million; the TTM figure through Mar 2026 stood at $485.4 million (up 284.96% YoY), while the FY2025 annual figure was $303.5 million, up 78.0% from the prior year.
- Assets Average grew to $485.4 million in Q1 2026 per VOR's latest filing, from $320.2 million in the prior quarter.
- Across five years, Assets Average topped out at $485.4 million in Q1 2026 and bottomed at $126.1 million in Q1 2025.
- Historically, Assets Average has averaged $224.2 million across 5 years, with a median of $215.5 million in 2022.
- Annual changes were most pronounced in 2024 — Assets Average tumbled 45.66% — and 2026, when it soared 284.96%.
- Vor Biopharma's Assets Average stood at $252.9 million in 2022, then slipped by 16.73% to $210.6 million in 2023, then tumbled by 38.53% to $129.4 million in 2024, then jumped by 147.36% to $320.2 million in 2025, then jumped by 51.61% to $485.4 million in 2026.
- Business Quant data shows VOR's Assets Average at $485.4 million in Q1 2026, $320.2 million in Q4 2025, and $190.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | 493.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 493.90 Mn |
| Mar 31, 2026 | 485.44 Mn |
| Dec 31, 2025 | 320.18 Mn |
| Sep 30, 2025 | 190.80 Mn |
| Jun 30, 2025 | 157.34 Mn |
| Mar 31, 2025 | 126.10 Mn |
| Dec 31, 2024 | 129.44 Mn |
| Sep 30, 2024 | 128.79 Mn |
| Jun 30, 2024 | 154.31 Mn |
| Mar 31, 2024 | 182.58 Mn |
| Dec 31, 2023 | 210.57 Mn |
| Sep 30, 2023 | 237.00 Mn |
| Jun 30, 2023 | 264.26 Mn |
| Mar 31, 2023 | 288.45 Mn |
| Dec 31, 2022 | 252.87 Mn |
| Sep 30, 2022 | 215.49 Mn |
| Jun 30, 2022 | 229.44 Mn |
| Mar 31, 2022 | 238.43 Mn |
| Dec 31, 2021 | 250.61 Mn |
| Sep 30, 2021 | 266.89 Mn |